Who are Rotarix (RV1)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rotateq vaccine, RotaTeq, Measles, mumps, rubella vaccine, BCG Solution, live attenuated Japanese encephalitis vaccine, Bacille Calmette Guerin (BCG).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rotarix-rv1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Rotarix (RV1) — Competitive Intelligence Brief

Rotarix (RV1) (Rotarix (RV1)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

marketed Live attenuated vaccine Rotavirus VP4 and VP7 surface proteins Immunology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Rotarix (RV1) (Rotarix (RV1)) — Telethon Kids Institute. Rotarix is a live attenuated rotavirus vaccine that stimulates the immune system to produce antibodies and cellular immunity against rotavirus infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Rotarix (RV1) TARGET	Rotarix (RV1)	Telethon Kids Institute	marketed	Live attenuated vaccine	Rotavirus VP4 and VP7 surface proteins
Rotateq vaccine	Rotateq vaccine	University Hospital, Brest	marketed	Live attenuated vaccine	Rotavirus VP4 and VP7 surface proteins
RotaTeq	RotaTeq	National Institute of Pediatrics, Mexico	marketed	Live attenuated vaccine	Rotavirus VP4 and VP7 surface proteins
Measles, mumps, rubella vaccine	Measles, mumps, rubella vaccine	PATH	marketed	Live attenuated vaccine
BCG Solution	BCG Solution	Alliance for Clinical Trials in Oncology	marketed	Live attenuated vaccine / Immunotherapy
live attenuated Japanese encephalitis vaccine	live attenuated Japanese encephalitis vaccine	Chinese Academy of Medical Sciences	marketed	Live attenuated vaccine
Bacille Calmette Guerin (BCG)	Bacille Calmette Guerin (BCG)	Bandim Health Project	marketed	Live attenuated vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rotarix (RV1) — Competitive Intelligence Brief. https://druglandscape.com/ci/rotarix-rv1. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab